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ABSTRACT 
 
LATENT TUBERCULOSIS INFECTION AND DYSLIPDEMIA AMONG REFUGEES 
ATTENDING A COMMUNITY BASED CLINIC IN GEORGIA 
By 
DOLGION ERDENEBAT 
JULY 23, 2018 
 
 
Background:  Emerging epidemiologic evidence indicates tuberculosis (TB) disease may increase 
the risk of non-communicable disease, including cardiovascular diseases (CVD). However, limited 
data exists on the association between latent TB infection (LTBI) and dyslipidemia, a key 
precursor to CVD. 
Objective: To determine the association between LTBI and dyslipidemia among newly arrived 
refugees to the US. 
Methods: We conducted a cross-sectional study among new refugees who received care at the 
DeKalb County Board of Health Refugee Clinic, Atlanta, Georgia between 1st October 2013 and 
31st August 2014. Eligible participants included adult refugees (age ≥21 years) who had valid 
QuantiFERON-TB Gold In-Tube (QFT) and blood lipid test results. Participants with a history of 
TB disease were excluded. QFT was used to define LTBI and dyslipidemia was defined by three 
blood lipid levels: total cholesterol, high-density lipoproteins (HDL), and triglycerides (TGL). 
Results: Among eligible participants (n=684), the prevalence of LTBI was 31.9%. Overall 30.6% 
(209/684) had elevated total cholesterol, 44% (301/684) had low HDL-C, and 40.7% (276/684) 
had elevated TGL. Participants with LTBI had a similar prevalence of elevated total cholesterol 
(35.3% vs 28.3%, p-value=0.06) and elevated triglycerides (44.5% vs 38.4%, p-value=0.13) 
compared to participants without LTBI. Low HDL-C was also similar in participants with and 
without LTBI (45.7 vs 40.4%, p-value=0.64). After adjusting for age, sex, body mass index and 
diabetes mellitus, LTBI was non-significantly associated with elevated total cholesterol (adjusted 
odds ratio [aOR] 1.27; 95%CI 0.89-1.82) and elevated triglycerides (aOR 1.18; 95% CI 0.84-1.67).  
Conclusion: Among recently arrived refugees in the US, we did not observe a statistically 
significant association between LTBI and dyslipidemia. Additional research is needed to 
determine mechanisms that may increase the risk of non-communicable disease in patients with 
TB disease and infection.  
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CHAPTER I 
INTRODUCTION 
1.1 Background 
Tuberculosis (TB) is an infectious disease caused by the Mycobacterium Tuberculosis (MTB) that 
mainly affects the lungs (WHO, 2017). Globally, TB is a leading public health problem causing 
high morbidity and mortality, particularly in low and middle-income countries (WHO, 2017). The 
World Health Organization (WHO) estimated that 10.4 million new TB cases occurred in 2016, 
affecting 6.2 million men, 3.2 million women and 1 million children. In 2016 TB was the ninth 
leading cause of death in the world, causing 1.7 million deaths (WHO, 2017).  An estimated 1.7 
billion people, one-quarter of world’s population, have latent TB infection (LTBI) which is an 
asymptomatic state consisting of MTB infection without bacteria activation (Houben & Dodd, 
2016). Simultaneously, the global burden of cardiovascular disease (CVD) is steadily increasing 
and it is estimated that 422.7 million people have CVD and 1.7 million attributable deaths occur 
annually (Roth et al., 2017). 
In recent years, studies indicate the association between TB and non-communicable disease, 
particularly cardiovascular diseases (Huaman, Henson, Ticona, Sterling, & Garvy, 2015). Studies 
reported that TB increases the risk of acute myocardial infarction (AMI) (Huaman et al., 2017), 
ischemic stroke (Sheu, Chiou, Kang, Chen, & Lin, 2010), and peripheral artery disease (Wang et 
al., 2017). Moreover, LTBI is associated with increased risk diabetes mellitus (DM) (Hensel et al., 
2016) and identified as independent risk factor of AMI (Huaman et al., 2018). There are several 
potential mechanisms which may explain how TB contributes to the CVD. First, MTB may affect 
the coronary artery and myocardium directly (Huaman et al., 2015).  
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Second, chronic inflammation during active TB replication and granuloma formation could cause 
impairment of endothelial, leading to atherosclerosis just as other chronic inflammation (Huaman 
et al., 2015). Last, TB infection may interrupt the lipid metabolism. Lipid abnormalities are the 
main risk factor of the CVD, increasing the risk by the 1.5-2 times (Ahmed et al., 2016; Orozco-
Beltran et al., 2017). Chronic inflammation, mediated by pro-inflammatory cytokines also has a 
potential effect on lipid metabolism (Elmehdawi, 2008). Low cholesterol was observed in patients 
with rheumatoid disorders and chronic bowl inflammatory disease (Elmehdawi, 2008). Similarly, 
patients with active TB had lower serum cholesterol comparing those without TB (Gebremicael et 
al., 2017). Cholesterol plays key role for replication, survival, dormancy, and reactivation of MTB 
(Brzostek, Pawelczyk, Rumijowska-Galewicz, Dziadek, & Dziadek, 2009; Rodriguez et al., 2014; 
Soto-Ramirez et al., 2017). MTB is capable of accumulating and utilizing cholesterol as an energy 
source and use it as protection from host immune-response and disrupt cholesterol metabolism at 
cellular level (Brzostek et al., 2009; Soto-Ramirez et al., 2017). Contrary, it is suggested that 
hypercholesterolemia could promote immunity impair towards TB infection and increase the TB 
susceptibility (Martens et al., 2008). However, whether lipid abnormalities support TB infection 
susceptibility or reverse relationship is not yet established. 
In 2015, the estimated global prevalence of dyslipidemia (high cholesterol) was 39% (37% for 
males and 40% for females) and the highest in Region of Europe with 54%, followed by the Region 
of the Americas (48%), Western Pacific (36.7%) and Southeast Asia (30.3%) (Benjamin et al., 
2017).  
Given the high population prevalence of dyslipidemia as well as LTBI, an improved understanding 
of the relationship between TB infection and lipid abnormalities have the potential to greatly 
impact clinical treatment and prevention programs for TB and non-communicable diseases.  
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The objective of the study was to determine the association between LTBI and blood lipid 
abnormalities among newly arrived refugees to the US at a community clinic in Dekalb County, 
Georgia. 
1.2 Gap and Purpose of Study   
To date, few studies have assessed the association between LTBI and non-communicable diseases, 
particularly lipid abnormalities. Given the high prevalence of lipid abnormalities and its role in the 
pathogenesis of non-communicable disease, an improved understanding of the association 
between LTBI and dyslipidemia has the potential to improve clinical care and public health 
practice.  
Our study addressed the association between LTBI prevalence and dyslipidemia, evaluating the 
the hypothesis that LTBI may increase the prevalence of  dyslipidemia.  
Therefore, we had following aims: 
1. To determine the prevalence of dyslipidemia among newly arrived refugees at Dekalb 
County, Atlanta, Georgia.  
2. To identify the cross-sectional association between LTBI and dyslipidemia. 
3. To define the association between LTBI and severity (level) of dyslipidemia. 
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CHAPTER II 
LITERATURE REVIEW 
2.1 Burden of LTBI 
LTBI is defined as “A state of persistent immune response to stimulation by Mycobacterium 
tuberculosis antigens with no evidence of clinically manifest active TB” (WHO, 2018).  It is 
estimated that 25% of the population (1.7 billion people) are infected with MTB (Houben & Dodd, 
2016). However, an estimated 10% of those with LTBI will develop TB disease in their lifetime, 
while rest of them contain the infection by developing granulomas. After 6-8 weeks of infection, 
due type IV hypersensitivity (delayed type hypersensitivity) to MTB, the granulomas undergo 
necrosis, causing death for most of the tuberculosis bacilli and leaving a small proportion of the 
bacilli surviving at the inactive stage and results in LTBI (Dutta & Karakousis, 2014). However, 
people with LTBI remain at risk of developing the active TB (lifetime risk 5-15%) and managing 
LTBI is the critical part for the reducing the high burden of TB (S. J. Lee et al., 2014). While the 
global prevalence was 23%, the highest prevalence observed in region of South East Asia with 
30.8%, followed by Western Pacific region (27.9%); African region (22.4%) and the American 
region (11.0%) and European region (13.7%) had the lower prevalence (Houben & Dodd, 2016). 
From the country-specific studies 31% of the population of Ethiopia had LTBI, while it was 49% 
in Uganda, 55.2% in South Africa (Basera, Ncayiyana, & Engel, 2017), 20% in Eastern China 
(Chen et al., 2015); and 28.6% in South Korea (S. J. Lee et al., 2014) . In the US, it is estimated 
that 12.4-13.6 million people had LTBI and 73% of them are non-US born (Mancuso, Diffenderfer, 
Ghassemieh, Horne, & Kao, 2016). LTBI is common among populations such as mining workers, 
health care providers and prisoners.  
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The prevalence of LTBI among healthcare workers of high TB burden counties was 47%, with the 
lowest as 37% (Brazil) and the highest as 64% (South Africa) (Nasreen, Shokoohi, & Malvankar-
Mehta, 2016). It was also documented high among miners with the prevalence of 89% (Hanifa et 
al., 2009), and 70.3% among prisoners in middle and high TB burden countries (70.3%) (Kawatsu, 
Uchimura, Izumi, & Ohkado, 2016). 
2.2 Burden of Dyslipidemia 
Dyslipidemia was defined as elevated cholesterol and triglycerides and lower high-density 
lipoproteins cholesterol (HDL-C) (American Association of Clinical Endocrinologists and 
American College of Endocrinology, 2017). Because it is the main risk factor of CVD, the 
dyslipidemia has become the public health problem (Najafipour et al., 2016). The low HDL 
increased the coronary heart disease risk (CHD) (adjusted risk ratio [aRR] 1.31, 95% confidence 
interval [CI] 1.18-1.45) among adults who are 30 years old and older in study from Spain (Orozco-
Beltran et al., 2017) and CVD risk by almost 2-fold (aHR 1.93, 95% CI 1.11-3.34) among adults 
four ethnic-race groups in US (Abd Alamir et al., 2018). The MESA also showed that 
hypercholesterolemia and lower HDL were significantly associated with higher Agatston CAC 
score (Abd Alamir et al., 2018). The adjusted prevalence ratio of elevated cholesterol and lower 
HDL was 1.55 (95% CI 1.26-1.92) and 1.2 (1.02-1.40) (Abd Alamir et al., 2018). The US study 
used Kaiser Permanente Southern California (KPSC) healthcare system found that elevated LDL 
and TGL increased the risk of CHD among US adults, while high HDL had protective effect with 
the hazard ratio of 1.49 (95% CI 1.38-1.61), 1.75 (95% CI 1.61-1.90) and 0.55 (95% CI 0.50-0.60) 
(Colantonio et al., 2016).  
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The prevalence of dyslipidemia is high globally, the estimated global prevalence was 39% (37% 
for males and 40% for females) and the highest in Region of Europe with 54%, followed by the 
Region of the Americas (48%), Western Pacific (36.7%) and Southeast Asia (30.3%) (Benjamin 
et al., 2017). The several studies indicated a high prevalence of dyslipidemia. The recent study in 
South Korea, the prevalence of dyslipidemia was 39.6% (J. Lee, Son, & Ryu, 2017) and similar 
result in China with 35.5% for dyslipidemia, 44.2% for hypertriglyceridemia and 14.7% for 
hypercholesterolemia (Qi et al., 2015) and Thailand with the prevalence of 29.6% for elevated 
LDL, 47.1% for lower HDL and 38.6% for hypertriglyceridemia (Aekplakorn et al., 2014). 
2.3 The association between LTBI and dyslipidemia 
The evidence on LTBI relating to dyslipidemia is scarce. However, the association between the 
TB and non-communicable disease, particularly the cardiovascular disease is documented in recent 
years.  The study in the US indicated that pulmonary tuberculosis increased the risk of AMI by 
almost 3 times (aHR 2·43, 95% CI 1·5–4·1) (Huaman et al., 2017) and from another population-
based study in Taiwan, 40% increased acute coronary syndrome among TB patients (Chung et al., 
2014). Besides, recent studies suggest the possible association between LTBI and CVD and 
metabolic disorder (Huaman et al., 2015; Huaman et al., 2018). The people with LTBI had 1.9 
times more odds having AMI (Huaman et al., 2018) and patients with DM were likely to have 
LTBI (aOR 2.3, CI 95% CI 1.2-4.5) compared to those without DM (Hensel et al., 2016).   
Various mechanisms potentially involved in TB and CVD association. Chronic inflammation, 
elevated pro-inflammatory cytokines caused by the TB granuloma formation could affect the 
coronary artery (tuberculosis arteritis) and myocardium (tuberculosis myocarditis) directly. Also 
could cause endothelial damage and subsequently the atherosclerosis (Huaman et al., 2015). In 
addition, TB infection could also be associated with lipid abnormalities, which are a primary risk 
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factor for CVD. The chronic inflammation, pro-inflammatory cytokines are known for association 
with lipid abnormalities (Elmehdawi, 2008).  The patients with chronic inflammation disorder such 
as rheumatoid disorders and chronic bowl inflammatory disease tend to have lower cholesterol 
(Elmehdawi, 2008).  Similar to other chronic inflammatory diseases, patients with active TB had 
lower cholesterol comparing those without TB (Gebremicael et al., 2017). On the other hand, 
hypercholesterolemia could delay the immune activity towards MTB infection and increase the 
risk of TB susceptibility (Martens et al., 2008). And at the cellular level cholesterol plays important 
role for MTB replication, survival, dormancy, and reactivation of MTB. MTB is capable of 
accumulating and utilizing cholesterol as important energy source and use it as protection from 
host immune-response and disrupt cellular cholesterol metabolism (Brzostek et al., 2009). 
However, whether lipid abnormalities support TB infection susceptibility or reverse relationship 
is not yet established. 
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2.4 Summary of literature review 
Highlights from the literature review:  
• LTBI prevalence globally is high, especially in low and middle-income countries and high-
risk populations such as miners, health care workers and prisoners.   
• LTBI might have possible contribution to the non-communicable diseases, in particular to 
DM and CVD 
• Many non-communicable diseases are risk factors for TB disease, reactivation of LTBI and 
poor TB outcome. However, recent evidences suggest the potential reverse association: 
that TB disease and LTBI may increase the risk of non-communicable diseases, particularly 
CVD. 
• There is a possibility that LTBI might play a role in lipid abnormalities which is a primary 
risk factor for CVD. The relationship between LTBI and dyslipidemia is under studied. 
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CHAPTER III 
MANUSCRIPT  
INTRODUCTION 
Tuberculosis (TB) remains an enormous public health problem, particularly in low-and middle-
income countries, whereas 97% of the reported cases are reported [1].  It is estimated that 10.4 
million new cases and 1.7 million deaths attributable to TB occurred in 2016 worldwide [1]. In 
addition, 25% of the world’s population (1.7 billion people) are infected with Mycobacterium 
tuberculosis (MTB), resulting in a non-infectious and subclinical state called latent TB infection 
(LTBI) [2]. Those with LTBI are at risk of reactivation and subsequent progression to TB disease 
[3]. Simultaneously, the global burden of cardiovascular disease (CVD) is steadily increasing and 
it is estimated that 422.7 million people have CVD and 17 million attributable death occur annually 
[4]. 
Emerging evidence suggests that TB disease and TB infection may be associated with non-
communicable diseases, in particular with CVD. The risk of acute myocardial infarction (AMI) 
[5] and ischemic stroke [6] and peripheral artery [7] disease was higher among TB patients. 
Additional evidence indicates that, LTBI is an independent risk factor of AMI [8]. TB disease or 
LTBI may contribute to CVD development by varying mechanisms. MTB could directly damage 
the myocardium (tuberculosis myocarditis) and coronary artery (tuberculosis arteritis) [9]. It is 
also possible that chronic immune activation towards MTB replication during the active TB 
disease may result in elevated production of pro-inflammatory cytokines which could lead to 
persistent inflammation and subsequent atherosclerosis [9]. Furthermore, TB infection could also 
be associated with lipid abnormalities, which are a primary risk factor for CVD development.  
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The chronic inflammation, pro-inflammatory cytokines are known for potential effect on lipid 
metabolism [10]. The low cholesterol was observed in patients with rheumatoid disorders and 
chronic bowl inflammatory disease [10]. Similarly, patients with active TB had lower serum 
cholesterol comparing those without TB [11]. Cholesterol plays key role for replication, survival, 
dormancy, and reactivation of MTB [12-14]. MTB is capable of accumulating and utilizing 
cholesterol as an energy source and use it as protection from host immune-response and disrupt 
cholesterol metabolism at cellular level [12, 13]. Contrary, it is suggested that 
hypercholesterolemia could promote immunity impair towards TB infection and increase the TB 
susceptibility [15].  
However, whether lipid abnormalities support TB infection susceptibility or reverse relationship 
is not yet established. 
Dyslipidemia increases the risk of CVD by almost 2 times [16, 17] and globally, 40% of the 
population has dyslipidemia [18]. Given the high population prevalence of dyslipidemia as well as 
LTBI, an improved understanding of the relationship between TB infection and lipid abnormalities 
has the potential to greatly impact clinical treatment and prevention programs for TB and non-
communicable diseases. The objective of the study was to determine the association between LTBI 
and blood lipid abnormalities among newly arrived refugees to the US at a community clinic in 
Dekalb County, Georgia. 
METHODS 
Study design and participants 
We conducted a cross-sectional study among refugees arriving to the US who received care at the 
DeKalb County Board of Health Refugee Clinic (Atlanta, Georgia, USA) between 1st October 
2013 and 31st August 2014.   
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Refugees received a general health exam and screening as standard of care, which included 
measures of blood lipids (total cholesterol, low-density lipoproteins [LDL-C], high-density 
lipoproteins [HDL-C], and triglycerides [TGL]) and the QuantiFERON-TB Gold In-Tube (QFT) 
test for LTBI. Other medical information such as demographic characteristics, clinical history, and 
a general blood chemistry panel were also collected as part of standard practice. Eligible 
participants included all adults aged ≥ 21 years, who received refugee status from the US 
Department of State, had valid blood lipid tests (total cholesterol, HDL-C, and TGL) and QFT 
results available, and were treated at the DeKalb County clinic during the study period. Patients 
with TB disease were excluded.   
Definitions 
The study’s primary exposure was LTBI defined by QFT test results. Patients were defined 
dichotomously as LTBI positive or negative according to manufacturer’s instructions [19]. 
The primary outcome of the study was dyslipidemia, defined using three measures: 1) elevated 
total cholesterol (hypercholesterolemia), 2) low HDL-C, and 3) elevated TGL 
(hypertriglyceridemia). Any dyslipidemia was defined as presence of hypercholesterolemia or 
lower HDL-C or hypertriglyceridemia [20].  We defined dyslipidemia according to the American 
Association of Clinical Endocrinology Guidelines for Management of Dyslipidemia 2017 (AACE 
2017) [21]; and Detection, Evaluation and Treatment of High Blood Cholesterol in Adults 2005 
(Adult Panel Treatment III, ATP III) [20].  Elevated total cholesterol was defined as total serum 
cholesterol ≥ 200 mg/dl or greater (normal defined < 200 mg/dl) [21].  
Low HDL-C was defined by serum HDL-C < 40 mg/dl in men and <50 mg/dl in women (normal 
defined 40 mg/dl or greater in men; 50 mg/dl or greater in women) [21]. Elevated TGL were 
defined by serum level ≥ 150mg/dl (normal defined <150mg/dl) [20] We also examined severity 
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of dyslipidemia using alternate classifications: Elevated total cholesterol was classified as 
“borderline high” with serum levels of 200-239 mg/dl and “high” ≥ 240 mg/dl; elevated TGL were 
classified as “borderline high” with serum levels of 150-199 mg/dl and “high” ≥ 200 mg/dl [20].  
Covariates extracted from patient medical records included age, sex, current smoking status, 
country of origin, alcohol use, blood pressure, body mass index (BMI), and diabetes mellitus (DM) 
status. Additional laboratory results including hemoglobin, white blood cell count, random 
glucose, creatinine, glycated hemoglobin (HbA1c), vitamin D level, human immunodeficiency 
virus (HIV) serologic, hepatitis B (HbsAb and HBsAg), hepatitis C antibody, and syphilis infection 
were also extracted.  
BMI was calculated as weight (kg)/height (m2).  BMI was classified as underweight (<18.5 
kg/m2), normal (18.5-24.9 kg/m2), overweight (25-29.9 kg/m2) and obese (≥30.0 kg/m2) [22]. TB 
incidence of the country of origin (TB cases per 100000 population annually) was defined 
according to World Health Organization (WHO) Report [23]. Country TB incidence classification 
was defined as moderate (<100), medium (100-199) and high (≥300) by WHO classification [23]. 
DM status was defined based on glycated hemoglobin (HbA1c) ≥ 6.5% according to the American 
Diabetes Association Guideline 2017 [24] and/or a previous history of DM diagnosis. Participants 
were classified as having pre-DM if HbA1c was between 5.7% and 6.4% and no previous diagnosis 
of DM diagnosis. 
We also assessed the association between LTBI and elevated LDL-C, combined dyslipidemia, and 
metabolic syndrome. Elevated LDL-C was defined as serum LDL-C ≥ 130 mg/dl. Combined 
dyslipidemia was defined as the presence of elevated LDL-C and hypertriglyceridemia.  
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An individual was categorized as having metabolic syndrome if they had all the following: high 
blood pressure (>140/90 mmHg), low HDL-C (less than 40 mg/dl in men, 50 mg/dl in women), 
high triglycerides   (≥150 mg/dl), and Glycated hemoglobin (HbA1c) with ≥5.6 mg/dl [20].    
 Statistical analyses 
Bivariate analyses were used to assess the association between patient characteristics and 1) LTBI 
and 2) Dyslipidemia. We used Chi-square tests for comparison of categorical variables, and 
Wilcoxon rank sum or T-tests for continuous variable comparisons. Multivariable logistic 
regression was used to estimate adjusted odds ratios (OR) and 95% confidence intervals (CI) for 
the association between LTBI and dyslipidemia; ordinal logistic regression was used to estimate 
the association between LTBI and severity of dyslipidemia. Covariates included in multivariable 
regression models were selected based on observed associations in bivariate analyses and previous 
studies (factors likely confounding the LTBI-dyslipidemia association) [17, 25-27]. All analyses 
were conducted using SAS 9.4. A two-sided P value <0.05 was considered statistically significant 
for all analyses.  
Ethics 
This study was reviewed and approved by the Institutional Review Boards at Georgia Department 
of Public Health and Georgia State University.   
RESULTS 
During the study period, medical information of 701 refugees who received care at the DeKalb 
County Board of Health Refugee Clinic between 1st October 2013 and 31st August 2014 was 
available. A total of 684 patients met study eligibility criteria and were included in the study 
(Figure 1). Median participant age was 33 years (IQR 27.0-42.0) and the majority were male 
(55.5% vs 44.5%).  
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Median body mass index (BMI) was 24.0 kg/m2 (IQR 21.0-27.2), 6.5% of participants were 
underweight, 29.8% were overweight, and 12.1% were obese. The prevalence of pre-DM was 
34.2% and DM prevalence was 7.8%. 
The overall prevalence of LTBI was 31.9% (218/684) (Table 1). Participants with LTBI were older 
(median age 35.5 vs. 32.0), more likely to be born in countries with higher TB incidence (71.7% 
vs. 61.4%) and have pre-DM or DM (52.8% vs. 37.0%) compared to participants without LTBI (p 
value <0.05 for all comparisons).  
Regarding lipid levels, the prevalence of elevated total cholesterol, low HDL-C and elevated TGL 
was 30.6% (209/684), 44% (301/684), and 40.7% (276/684) respectively (Table 2). Median total 
cholesterol was 180 mg/dl (IQR 155.5-209.0), median HDL-C was 46 mg/dl (IQR 39.0-53.5), and 
median TGL was 128 mg/dl (IQR 87.5-191.5). Hypercholesterolemia was more common among 
those who were older (median age 39 vs. 31), male (37.0% vs.22.6%), had higher BMI (median 
BMI 28.6 kg/m2 vs.23.5 kg/m2) and pre-DM (34.0% vs.24.5%) or DM (56.6% vs. 24.0%) (p value 
<0.05 for all results). Similarly, hypertriglyceridemia was higher in those who were older (median 
age 36 vs. 30), male (50.5% vs.27.9%), had higher BMI (median BMI 25.7 kg/m2 vs.22.9 kg/m2) 
and pre-DM (47.0% vs.32.8%) or DM (66% vs. 32.8%) (p value<0.05 for the all results). 
Prevalence of low HDL-C was higher among females (58.5% vs 32.4%), those who had higher 
BMI (median BMI 25.1 kg/m2 vs.23.3 kg/m2) and pre-DM (50.0% vs.38.4%) or DM (56.4% vs. 
38.4%) (p value <0.05 for all results).  
Compared to participants without LTBI, those with LTBI had non-significantly higher proportions 
of elevated total cholesterol (28.3% vs.35.3%, p value=0.06) and elevated TGL (38.4% vs. 44.5%p 
value=0.13). More participants with LTBI had low HDL-C levels compared to those without LTBI 
(40.4% vs. 45.7% p-value=0.64). A non-significantly higher proportion of any dyslipidemia was 
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observed among participants with LTBI compared to than those without LTBI (72.9% vs 69.8%, 
p value=0.39) (Table 1).  
Total cholesterol was non-significantly higher among participants with LTBI (median total 
cholesterol 184 mg/dl, IQR 159-213) than those without LTBI (median total cholesterol 178 mg/dl, 
IQR  153-205) (p value=0.05). There was no difference in median HDL-C between those with 
LTBI (median HDL-C 46 mg/dl, IQR 38-53) and without LTBI (median HDL-C 46 mg/dl, IQR 
38-53) (p value=0.19). Also, TGL was non-significantly higher in participants with LTBI (median 
TGL 134 mg/dl, IQR 87-202) compare to participants without LTBI (median TGL 128 mg/dl, IQR 
88-188) (p value=0.35) (Table 1). 
After adjusting for age, sex, body mass index and DM status, the odds of having 
hypercholesterolemia among those with LTBI was 1.3 (95% confidence interval [CI] 0.9-1.8) 
times the odds among those without LTBI (Table 3).  In a similarly adjusted model, the odds of 
having low HDL-C was 0.77 (95% CI 0.54-1.07) times the odds of those without LTBI. Third, the 
odds of having elevated TGL among participants with LTBI was 1.18 (95% CI 0.84-1.67) times 
the odds of elevated TGL among participants without LTBI.  
Additionally, LTBI was not significantly associated with elevated LDL-C, combined 
dyslipidemia, or metabolic syndrome (Supplementary Table 2).  
Moreover, among the participants with DM, high LTBI presence was observed in those who have 
elevated cholesterol (46.7%), low HDL-C (50.0%) and elevated TGL (48.6%) (supp table 4.). 
There was significant effect of elevated cholesterol and TGL on LTBI presence among who had 
normal BMI (18.5-24.9 kg/m2). The odds of LTBI among with elevated cholesterol (aOR 1.88, 
95% CI 1.13-3.14) was higher than ones with normal cholesterol. Similarly, odds of LTBI in those 
with elevated TGL was higher (aOR 1.65, 95% CI 1.03-2.65) compared to ones with normal TGL.   
 22 
 
DISCUSSION 
We found that seven in ten refugees attending a community health clinic had at least one blood 
lipid abnormality and nearly one in three had LTBI. Although we observed trends toward increased 
dyslipidemia in patients with LTBI, we did not report a statistically significant association between 
LTBI and elevated total cholesterol, low HDL-C, or elevated TGL. Similarly, the presence of LTBI 
had no significant association with degree of dyslipidemia level. However, our study observed 
high proportion of LTBI among the participants with DM and dyslipidemia, with half of the people 
with DM and dyslipidemia had LTBI.  
Only a limited number of studies have previously estimated the association between TB disease or 
LTBI presence with blood lipid abnormalities. A propensity scores matched analysis of data from 
the 2011-2012 National Health Nutritional Examination Survey (NHANES) reported no 
significant association between LTBI defined by QFT and dyslipidemia. The prevalence of 
elevated total cholesterol (>200 mg/dl) was same in the group with LTBI (44.7%) as it was in the 
non-LTBI group (44.2%) (p value=0.8). Similar outcomes for the prevalence of elevated TGL 
(>150 mg/dl) (24.0% vs 28.7%, p value=0.227) and low HDL-C (<40 mg/dl) (20.0% vs.17.4%, p 
value=0.336) were observed among two groups [28]. 
Conversely, studies assessing the relationship between dyslipidemia and TB disease have reported 
significant differences in cholesterol levels among patients with pulmonary TB (PTB) compared 
to those without. For example, a retrospective cohort study, involving the adults with active PTB 
who received care at a Turkish Armed Forces and primary care facility reported a significantly 
lower lipid profile in PTB patients compared to healthy controls [29]. The PTB were (both smear 
positive and negative) and diagnosed regarding sputum culture, chest X-ray and clinical 
presentation.   
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Compared to those without PTB, participants with PTB had lower total cholesterol (mean total 
cholesterol 127.6 mg/dl vs 150.8 mmol/l), LDL-C (mean LDL-C 81.2 vs. 88.9 mg/dl) and HDL-
C (mean HDL-C 30.9 mg/dl vs 42.5 mg/dl) (p value<0.05 for all comparisons). Furthermore, 
having lower cholesterol and HDL-C presence was correlated with degree of pulmonary damage 
among the participants with PTB. The patients with more radiological extend (radiological) tend 
to have lower cholesterol (r=-0.43, p value<0.01) and HDL-C (r=-0.60, p<0.01) [29]. An additional 
case-control study in Turkey, conducted among active TB patients (smear and culture positive), 
and patients with pneumonia and healthy controls reported the similar results [30]. TB patients had 
lower serum total cholesterol (mean TC 137.21 vs.164.30 mg/dl), HDL-C (mean HDL-C 
33.25mg/dl vs.48.6 mg/dl), and TGL (mean TGL 66.51 vs.107.43 mg/dl) compared to the control 
group (p value<0.05 for all comparison) [30]. Lastly, a 2016 cohort study conducted among new 
TB patients, who are between 25 and 60 years old in South India showed different levels of LDL-
C, TGL and HDL-C by DM status (known DM [KDM], new DM diagnosis [NDM] and without 
DM [NG])  [31]. Participants with TB and KDM had higher serum LDL-C (mean LDL-C 97 mg/dl 
vs. 87 mg/dl vs. 83 mg/dl, p value=0.004) and HDL-C (mean HDL-C 38 mg/dl vs. 33 mg/dl vs. 
37 mg/dl, p value=0.013) and TGL (mean TGL 111 mg/dl vs. 100 mg/dl vs. 73 mg/dl, p 
value<0.001) than participants with TB and NDM and NG [31].  
Despite not observing a significant association in this study between LTIB and dyslipidemia, it is 
plausible for existing relationship. In our study, majority of our participants was at young age, 
65.3% of them aged between 25-44 years old and normal range of BMI (51.6%). Yet we observed 
high prevalence of dyslipidemia alongside with high prevalence of LTBI. Moreover, there are 
plausible mechanisms which LTIB could increase the risk of metabolic diseases. Increasing 
evidence suggests there is an association between LTBI and DM, but whether the relationship 
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results from DM increasing the risk of LTBI or vice versa has not been established. Our results 
suggest that if LTBI increases the risk of DM it may do so independently of dyslipidemia.  We 
reported high prevalence of LTBI among participants with DM and dyslipidemia, encouraging the 
screening of LTBI among refugees with DM and dyslipidemia in clinical setting.  Cholesterol does 
play an important role in MTB infection, serving as a source of energy for the bacteria and 
providing protection from host immune response which promote MTB persistence [12]. Because 
MTB expends cholesterol, there is a possibility that persons with LTBI who have ongoing bacterial 
replication may in turn have lower cholesterol levels. 
Our study was subject to limitations. First, our study only included state sponsored refugees to the 
US, therefore our results are not widely generalizable to the US general population. Second, our 
study only measured blood lipid levels at one point in time. Diet, alcohol use, stress and strenuous 
exercise before the test may have impacted the lipid test results [32] and therefore we may have 
misclassified participants based on dyslipidemia status. Also, clinical information related to 
previous diagnosis and treatment of high cholesterol and triglycerides were not available. Third, 
the study was cross-sectional in nature. Hence, we were not able to determine if dyslipidemia 
(outcome) preceded LTBI (exposure) or assess the temporal relationship. Fourth, we used a QFT 
test to diagnose LTBI. Currently all LTBI tests do not directly measure MTB presence, and 
because QFT relies on an antigen response it is likely that some misclassification of LTBI 
occurred. Nonetheless, our study population consisted primarily of persons who had previous BCG 
vaccination and therefore the QFT was the best available LTBI test. Last, it is possible that the 
relatively small sample size of our study population could have affected the statistical power to 
detect a relationship between LTBI and dyslipidemia.  
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Conclusion 
TB and CVD have huge burdens globally, especially in the developing countries. Prominently, 
suggestions on the association between TB and CVD are rising, and improved understanding of 
this relationship has become crucial for the public health significance. As lipids play and important 
role in both CVD and TB disease development, it was important to address the potential 
relationship between TB infection and lipid abnormalities. Even though we did not observe 
statistically significant associations, our study reports high prevalence of dyslipidemia and LTBI 
among refugees arrived in US, suggesting the further exploration on relationship between TB 
infection and lipid abnormalities.  
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Figure 1. Flow chart of study participants 
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LIST OF TABLES 
Table 1. Characteristics of participants with LTBI, Dekalb County Refugee Clinic, 2013-2014 
Characteristics QFT negative QFT positive Total p-value 
 (n= 466, 68.1%) (n=218, 31.9%) (n=684, 100%)  
 n (%) n (%) n (%)  
Demographics 
 
Age, years 
     Median (IQR)    32.0 (26.5-41.0) 35.5 (28.0-47.0) 33.0 (27.0-42.0) <0.01* 
     <25       75 (16.2)   22 (10.3)       97 (14.3)  
 
0.01* 
     25-44      308 (66.4)       134 (62.6)     442 (65.2) 
     45-64        65 (14.0)     46 (21.5)     111 (16.4) 
     ≥65        16 (3.4)          12 (5.6)       28 (4.1) 
     Missing          2            4         6 
Sex 
     Male 252 (54.4) 124 (57.9)      376 (55.5)  
0.39      Female 211 (45.6)   90 (42.1)      301 (44.5) 
     Missing            3           4          7 
Country of origin 
    Butan   99 (21.2) 60 (27.8) 159 (23.3)  
 
<0.01* 
    Burma 147 (31.6) 66 (30.6) 213 (31.2) 
    Iraq   70 (15.0)        12 (5.6)   82 (12.0) 
    Somalia 33 (7.1)         34 (15.8)        67 (9.8) 
    Other 117 (25.1)         44 (20.0)       161 (23.6) 
    Missing 0          2             2 
TB incidence of country of origin# 
     <100 152 (32.6) 49 (22.7) 201 (29.5) <0.01* 
    100-299 125 (26.8) 84 (38.9) 209 (30.7) 
    ≥300 161 (34.6) 71 (32.8) 232 (34.0) 
    Unknown 28 (6.0) 12 (5.6) 40 (5.8) 
    Missing 0 2 2 
Current smoker 
    No 352 (76.9) 162 (76.4)       514 (76.7)  
0.90     Yes 106 (23.1)   50 (23.6)       156 (23.3) 
     Missing            8           6         14  
Alcohol abuse 
     No 347 (77.3) 169 (79.3) 516 (78.0)  
0.55      Yes 102 (22.7)  44 (20.7) 146 (22.0) 
     Missing          17           5           22 
Clinical information 
Blood pressure, mmHg 
     Normal (<120/80) 235 (50.5) 113 (52.1) 348 (51.0)  
 
0.95 
     Pre-HTN (120-139/80-89) 158 (34.0) 72 (33.2)  230 (33.7) 
     Stage 1-HTN (140-159/90-99)     61 (13.1)  26 (12.0)    87 (12.8) 
     Stage 2-HTN (>160/100)           11 (2.4)   6 (2.7)   17 (2.5) 
     Missing             1           1              2 
BMI, kg/m2 
     Median (IQR) 23.9 (21.1-27.1) 24.1 (20.8-27.3) 24.0 (21.0-27.2) 0.84 
     <18.5 29 (6.3) 15 (7.0) 44 (6.5)  
0.14      18.5-24.9        243 (52.8) 105 (48.8) 348 (51.6) 
     25-29.9        126 (27.4)   75 (34.9) 201 (29.8) 
     ≥30          62 (13.5) 20 (9.3)    82 (12.1) 
     Missing            3           6             9  
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DM status 
     No DM 291 (63.0) 102 (47.2) 393 (58.0)  
<0.01*      Pre-DM 141 (30.5)   91 (42.1) 232 (34.2) 
     DM          30 (6.5)         23 (10.7)           53 (7.8) 
     Missing            4           2             6 
Hemoglobin, g/dl 
     Median (IQR) 14.5 (13.0-15.6) 14.6 (13.4-15.5) 14.6 (13.1-15.6) 0.41 
White blood cell, x109/l 
     Median (IQR) 7.2 (5.9-8.5) 7.0 (5.8-8.2) 7.1 (5.9-8.4) 0.21 
Random glucose, mg/dl 
     Median (IQR) 92 (86-99) 92 (87-105) 92 (86-101) 0.14 
Creatinine, mg/dl 
     Median (IQR) 0.8 (0.6-0.9) 0.8 (0.6-0.9) 0.8 (0.6-0.9) 0.52 
Glycated hemoglobin, % 
     Median (IQR) 5.5 (5.3-5.8) 5.7 (5.4-6.0) 5.6 (5.4-5.8) <0.01* 
Vitamin D, ng/ml 
     Median (IQR) 20 (15-27) 21 (16-27) 21 (15-27) 0.46 
     <20 207 (44.7) 83 (38.4) 290 (42.7) 0.10 
     20-30 170 (36.7) 98 (45.4) 268 (39.5)  
     >30    86 (18.6) 35 (16.2) 121 (17.8)  
     Missing            3          2             5  
HIV status 
     Negative 458 (98.7) 213 (98.2) 671 (98.5)  
0.58      Positive   6 (1.3) 4 (1.8) 10 (1.5) 
     Missing            2           1             3 
Syphilis, rapid plasma reagan test 
     Negative 456 (97.8) 214 (98.6) 670 (98.1) 0.49 
     Positive 10 (2.2)   3 (1.4) 13 (1.9) 
     Missing            0            1             1 
Hepatitis B, HBsAg 
     Negative 453 (97.4) 212 (97.7) 665 (97.5)  
0.83      Positive 12 (2.6)   5 (2.3) 17 (2.5) 
     Missing            1            1             2 
Hepatitis B, HBsAb 
     Negative 205 (44.1) 74 (34.1) 279 (40.9)  
0.01*      Positive 260 (55.9) 143 (65.9) 403 (59.1) 
     Missing            1            1             2 
Hepatitis C, antibody 
    Negative 334 (71.8) 141 (64.7) 475 (69.6)  
0.05*     Positive 131 (21.2)   77 (35.3) 208 (30.4) 
    Missing            1           0             1 
Blood lipid information 
Total cholesterol, mg/dl 
     Median (IQR)       178 (153-205)    184 (159-213) 180 (155.5-209) 0.15 
     ≤130 (low) 34 (7.3)         12 (5.5) 46 (6.7)  
     130< and >200 (normal)        300 (64.4) 129 (64.7) 429 (69.4) 0.06 
     ≥200 (elevated)        132 (28.3)   77 (35.3) 209 (30.6) 
HDL-C, mg/dl + 
     Median (IQR)  46 (39-54) 46 (38-53) 46 (39.0-53.5) 0.19 
     Lower 213 (45.7)   88 (40.4) 301 (44.0) 0.64 
     Normal 253 (54.3) 130 (59.6)         383 (56.0)  
TGL, mg/dl 
     Median (IQR) 127 (88-188) 134 (87-202) 128 (87.5-191.5) 0.35 
     <150 (normal) 287 (61.6) 121 (55.5) 408 (59.7) 0.13 
     ≥150 (elevated) 179 (38.4)   97 (44.5) 276 (40.3)  
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Total Cholesterol (log) 
     Mean (SD) 5.18 (0.21) 5.21 (0.21) 5.19 (0.21) 0.05* 
HDL-C (log) 
     Mean (SD) 3.81 (0.24) 3.80 (0.25) 3.81 (0.24) 0.57 
TGL (log) 
     Median (IQR) 4.8 (4.5-5.2) 4.9 (4.5-5.3) 4.85 (4.5-5.3) 0.35 
Total cholesterol level, mg/dl     
     Normal (160-199) 334 (71.7) 141 (64.7) 475 (69.4)  
 
0.11 
     Borderline high (200-239)   89 (19.1)   47 (21.6) 136 (19.9) 
     High (≥240) 43 (9.2)    30 (13.7)   73 (10.7) 
TGL level, mg/dl 
     Optimal (<150) 287 (61.6) 121 (55.5) 408 (59.6)  
0.31      Borderline high (150-199)   75 (16.1)   42 (19.3) 117 (17.1) 
     High (≥200) 104 (22.3)    55 (25.2) 159 (23.3) 
Any dyslipidemia ++  
     Yes 325 (69.8) 159 (72.9) 484 (70.8) 0.39 
     No  142 (30.2)         59 (27.1)         200 (29.2) 
 
*-Statistically significant, Chi-square (categorical) or Wilcoxon test (medians) or T-test (means), 
 two-sided p-value <0.05 
#- Incidence of active TB case per 100 000 population, WHO Global Tuberculosis Report 2014 
+- HDL-C defined different in male and female. Lower (<40 mg/dl in male, <50 mg/dl in female) and normal (≥40 mg/dl 
in male, ≥50 mg/dl in female) 
++-Any dyslipidemia defined as elevated total cholesterol (≥200 mg/dl) OR lower HDL-C (<40 mg/dl in male, <50 mg/dl 
in female) OR elevated TGL (≥150 mg/dl) 
LTBI= Latent TB Infection, QFT= QuantiFERON®-TB Gold in-Tube test, IQR=Interquartile range, TB=Tuberculosis, 
HTN=Hypertension, BMI=Body mass index, DM=Diabetes Mellitus, HIV=Human immunodeficiency virus, HBsAg= 
Hepatitis B surface antigen, HBsAb= Hepatitis surface antibody, HDL-C =High density lipoprotein, TGL=Triglycerides, 
SD=Standard Deviation, WHO-World Health Organization. 
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Table 2. Characteristics of participants by total cholesterol, HDL-C and TGL, Dekalb County Refugee Clinic, 2013-2014 
Characteristics Total Cholesterol+  HDL-C++  TGL+++  
 Normal Elevated p-value Normal  Lower p-value Normal Elevated p-value 
 n=475 (69.4%) n=209 (30.6%)  n=383 (56.0%) n=301 (44.0%)  n=408 (59.7%) n=276 (40.7%)  
 n (%) n (%)  n (%) n (%)  n (%) n (%)  
 
Demographics 
Age, years 
     Median (IQR) 31 (26-39) 39 (31-50) <0.01* 32 (26-41) 33 (27-44) 0.12 30 (25-39) 36 (29-50) <0.01* 
     <25    81 (83.5)   16 (16.5)  
 
<0.01* 
   57 (58.8)    40 (41.2)  
 
0.63 
   74 (76.3)  23 (23.7)  
 
<0.01* 
     25-44 320 (72.4) 122 (27.6)  249 (56.3)   193 (43.7) 274 (62.0) 168 (38.0) 
     45-64   55 (49.6)   56 (50.4)    56 (50.4)    55 (49.6)    42 (37.8)   69 (62.2) 
     ≥65       16 (57.1)   12 (42.9)    15 (53.6)    13 (46.4)    13 (46.4)   15 (53.6) 
     Missing         3          3               6             0           5          1 
Sex 
     Male 237 (63.0) 139 (37.0) <0.01* 254 (67.6) 122 (32.4) <0.01* 186 (49.5) 190 (50.5) <0.01* 
     Female 233 (77.4)   68 (22.6) 125 (41.5) 176 (58.5) 217 (72.1)    84 (27.9) 
     Missing          5          2              4              3          5          2 
Country of origin# 
    Butan 104 (65.4) 55 (34.6) 0.11 
 
 
  83 (52.2) 76 (47.8) <0.01* 
 
  78 (49.1)  81 (50.9) 0.05 
 
 
    Burma 139 (65.3) 74 (34.7) 129 (60.6) 84 (29.4) 132 (62.0)  81 (38.0) 
    Iraq   62 (75.6) 20 (24.4)   36 (43.9)  46 (56.1)   51 (62.2)   31 (37.8) 
    Somalia        47 (70.2)       20 (29.8)   31 (46.3)  36 (53.7)   43 (64.2)   24 (36.8) 
    Other      122 (75.8)       39 (24.2)         102 (63.4)        59 (36.6)         102 (63.4)         59 (36.6) 
    Missing          1          1              2          0              2           0  
TB incidence of country of origin# 
     <100 144 (71.6) 57 (28.4)  
 
0.73 
 
 
101 (50.2) 100 (49.8)  
 
<0.01* 
122 (60.7)  79 (39.3)  
 
 
    100-299 147 (70.3) 62 (29.7) 108 (51.7) 101 (48.3) 111 (53.1)  98 (46.9) 
    ≥300 155 (66.8) 77 (33.2) 142 (61.2)   90 (38.8) 145 (62.5)   87 (37.5) 
    Unknown        28 (70.0)       12 (30.0)   30 (75.0)   10 (25.0)   28 (70.0)   12 (30.0) 
    Missing          1         1              2             0           2          0 
Current smoker 
    No 362 (70.4) 152 (29.6)  
0.18 
286 (55.6) 228 (44.4)  
0.86 
323 (62.8) 191 (37.2)  
<0.01*     Yes 101 (64.7)   55 (35.3)   88 (56.4)    68 (43.4)  74 (47.4)   82 (52.6) 
     Missing        12          2              9              5          11           3 
Alcohol abuse 
     No 369 (71.5) 147 (28.5)  
<0.01* 
277 (53.7) 239 (46.3)  
<0.01* 
326 (63.2) 190 (39.8)  
<0.01*      Yes    87 (59.6)   59 (40.4)    98 (67.1)    48 (32.9)   67 (45.9)   79 (54.1) 
     Missing        19          3             8          14          15          7 
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Clinical information 
 
Blood pressure, mmHg 
    Normal   (<120/80) 269 (77.3) 79 (22.7)  
 
<0.01* 
189 (54.3) 159 (46.7)  
 
0.67 
254 (73.0)    94 (27.0)  
 
<0.01* 
    Pre-HTN (120-139/80-89)  143 (62.2)  87 (37.8) 136 (59.1)    94 (40.9) 114 (49.6) 116 (50.4) 
    Stage 1-HTN (140-159/90-99)    51 (58.6)  36 (41.4)   47 (54.0)     40 (46.0)   31 (35.6)    56 (64.4) 
    Stage 2-HTN (>160/100)    10 (58.2)   7 (41.2)     9 (47.1)       8 (52.9)   7 (41.2)   10 (58.8) 
     Missing          2         0              0              2          2          0 
 
BMI, kg/m2 
     Median (IQR) 23.5 
(20.6-26.6) 
28.6 
(22.6-28.3) 
<0.01* 23.3 
(20.5-26.1) 
25.1 
(22.0-28.4) 
<0.01* 22.9 
(20.3-26.3) 
25.7 
(22.9-28.2) 
<0.01* 
     <18.5   41 (79.6)  12 (20.4)  
<0.01* 
30 (68.2) 14 (31.8)  
<0.01* 
  38 (86.4)     6 (13.6)  
<0.01* 
     18.5-24.9 262 (75.3)   86 (24.7) 215 (61.8) 133 (38.2) 230 (66.1) 118 (33.9) 
     25-29.9 126 (69.7)   75 (30.3)    99 (49.3) 102 (50.7)   96 (47.7) 105 (52.3) 
     ≥30   46 (56.1)   36 (43.9)   33 (40.2)   49 (59.8)   38 (46.3)   44 (53.6) 
     Missing          5          4               3              6            6          3  
DM status 
     No DM 293 (74.5) 100 (24.5)  
<0.01* 
242 (61.6) 151 (38.4)  
<0.01* 
264 (67.2) 129 (32.8)  
<0.01* 
     Pre-DM 153 (66.0)   79 (34.0) 116 (50.0) 116 (50.0) 123 (53.0) 109 (47.0) 
     DM   23 (43.4)   30 (56.6)   23 (43.4)    30 (56.4)   18 (34.0)    35 (66.0) 
     Missing          6          0              2              4 3 3 
Hemoglobin, g/dl 
     Median (IQR) 14.1 
(12.9-15.5) 
15.1 
(13.9-16.0) 
<0.01* 14.8 
(13.5-15.6) 
14.0 
(12.7-15.5) 
<0.01* 13.9 
(12.8-15.3) 
15.1 
(13.9-16.0) 
<0.01* 
White blood cell, x109/l 
     Median (IQR) 7.1 (5.7-8.2) 7.3 (6.1-8.6) 0.06 7.0 (5.7-8.3) 7.2 (6.1-8.5) 0.07 6.8 (5.6-7.9) 7.5 (6.4-8.8) <0.01* 
Random glucose, mg/dl 
     Median (IQR) 91 (85-98) 95 (88-106) <0.01* 92 (86-99) 92 (85-104) 0.71 90 (85-97) 95 (88-106) <0.01* 
Creatinine, mg/dl 
     Median (IQR) 0.8 (0.6-0.9) 0.9 (0.7-1.0) <0.01* 0.8 (0.7-0.9) 0.7 (0.6-0.9) <0.01* 0.7 (0.6-0.9) 0.9 (0.7-1.0) <0.01* 
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Glycated hemoglobin, % 
     Median (IQR) 5.5 (5.3-5.8) 5.7 (5.4-6.0) <0.01* 5.5 (5.3-5.8) 5.6 (5.4-5.9) <0.01* 5.5 (5.3-5.7) 5.7 (5.4-6.0) <0.01* 
Vitamin D, ng/ml 
     Median (IQR) 20 (15-26) 22 (16-28) 0.06 21 (16-28) 20 (14-25) <0.01* 20 (15-26) 22 (16-28) 0.01* 
     <20 214 (73.8) 76 (26.2)  149 (51.4) 141 (48.6)  186 (64.1) 104 (35.9)  
     20-30      178 (66.4)               90 (33.6) 0.08 156 (58.2) 112 (41.8) 0.11 157 (58.6) 111 (41.4)  
     >30        78 (64.5)       43 (35.6)    74 (61.2)   47 (38.8)  62 (51.2) 59 (48.8)  
     Missing          5         0                1              4           3         2  
HIV status 
     Negative 465 (69.3) 206 (30.7)  
0.96 
375 (55.9) 296 (44.1)  
0.71 
398 (59.3) 273 (40.7)  
0.49 
     Positive     7 (70.0)     3 (30.0)     5 (50.0)     5 (50.0)    7 (70.0)     3 (30.0) 
     Missing          3                                    0              3             0           3          0 
Syphilis, rapid plasma reagan test 
     Negative 466 (69.6) 204 (30.4)  
0.53 
373 (55.7) 297 (44.3)  
0.33 
400 (59.7) 270 (40.3)  
0.67 
     Positive     8 (61.5)      5 (38.5)     9 (69.2)     4 (30.2)   7 (53.9)    6 (46.1) 
     Missing           1          0              1              0           1         0 
Hepatitis B, HBsAg 
     Negative 462 (69.5) 203 (30.5)  
0.67 
371 (55.8) 294 (44.2)  
0.8 
391 (58.8) 274 (41.2)  
0.01* 
     Positive   11 (64.7)     6 (35.3)    10 (58.8)      7 (41.2)  15 (88.2)   2 (11.8) 
     Missing          2          0               2              0           2         0 
 
 
Hepatitis B, HBsAb 
     Negative 203 (72.8)    76 (27.2)  
0.11 
153 (54.8) 126 (45.2)  
0.61 
187 (67.0) 92 (33.0)  
<0.01* 
     Positive 270 (67.0)  133 (33.0) 229 (56.8) 174 (43.2) 220 (54.6) 183 (45.4) 
     Missing          2          0              1              1           1          1 
Hepatitis C, antibody 
    Negative 340 (71.6) 135 (28.4)  
0.06 
268 (56.4) 207 (43.6)  
0.7 
284 (59.8) 191 (40.2)  
0.87 
    Positive 134 (64.4)   74 (35.6) 114 (54.8)   94 (45.2) 123 (59.1)   85 (40.9) 
    Missing           1                1              0          1  
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LTBI  
    QFT Negative 334 (71.7) 132 (28.3) 0.06 253 (54.3) 213 (46.7) 0.19 287 (61.6) 179 (38.4) 0.13 
    QFT Positive 141 (64.7)   77 (35.3) 130 (59.6)    88 (40.4) 121 (55.5)   97 (44.5) 
 
+- Total cholesterol defined as normal (<200 mg/dl) and elevated (≥200 mg/dl). 
++- HDL-C defined different in male and female. Normal (≥40 mg/dl in male, ≥50 mg/dl in female) and lower (<40 mg/dl in male, <50 mg/dl in female). 
+++- TGL defined as normal (<150 mg/dl) and elevated (≥150 mg/dl). 
*-Statistically significant, Chi-square (categorical) or Wilcoxon test (medians), two-sided p-value <0.05 
#- Incidence of active TB case per 100 000 population, WHO Global Tuberculosis Report 2014 
IQR=Interquartile range, TB=Tuberculosis, HTN=Hypertension, BMI= Body mass index, DM=Diabetes Mellitus, HIV=Human immunodeficiency virus, HBsAg= Hepatitis B 
surface antigen, HBsAb= Hepatitis surface antibody, HDL-C =High density lipoprotein, TGL=Triglycerides, LTBI= Latent TB Infection, QFT= QuantiFERON®-TB Gold in-Tube 
test, WHO-World Health Organization. 
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Table 3. Association between latent TB infection and dyslipidemia (total cholesterol, HDL-C and 
TGL) 
 
 Crude OR (95% CI) Adjusted OR (95% CI) * 
TOTAL CHOLESTEROL 
Odds of total cholesterol as ≥ 200 mg/dl (binary logistic regression, n=684) 
LTBI negative Ref Ref 
LTBI positive 1.38 (0.98-1.95) 1.27 (0.89-1.82) 
Odds of total cholesterol as 200-239 mg/dl and ≥240 mg/dl (ordinal logistic regression, n=684) 
LTBI negative Ref Ref 
LTBI positive 1.41 (1.01-1.97) 1.31 (0.93-1.86) 
HDL-C 
Odds of HDL-C as ≤ 40 mg/dl in male and ≤ 50 mg/dl in female (binary logistic regression, n=684) 
LTBI negative Ref Ref 
LTBI positive 0.80 (0.58-1.11) 0.77 (0.54-1.07) 
TGL 
Odds of TGL ≥ as 150 mg/dl (binary logistic regression, n=684) 
LTBI negative Ref Ref 
LTBI positive 1.29 (0.93-1.78) 1.18 (0.84-1.67) 
Odds of TGL as 150-199 mg/dl and ≥200 mg/dl (ordinal logistic regression, n=684) 
LTBI negative Ref Ref 
LTBI positive 1.25 (0.91-1.71) 1.13 (0.81-1.56) 
 
*-Adjusted for age group, gender, body mass index, and diabetes mellitus 
#-Only binary logistic regression analysis was conducted on HDL-C 
-Missing values of covariates were coded as level of covariates 
LTBI= Latent TB Infection, HDL-C =High density lipoprotein, TGL=Triglycerides, OR=Odds ratio, CI=Confidence 
interval 
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Supplemental Table 1. Characteristics of participants by LDL-C, Metabolic syndrome and Combined dyslipidemia, Dekalb County, Refugee Clinic 
 
Characteristics LDL-C+  Metabolic syndrome++  Combined Dyslipidemia+++  
 Normal Elevated p-value No Yes p-value No Yes p-value 
 n=514 (78.5%) n=141 (21.5%)  n=653 (96.3%) n=25 (3.7%)  n=572 (87.3%) n=83 (12.7%)  
 n (%) n (%)  n (%) n (%)  n (%) n (%)  
 
Demographics 
 
Age, years 
     Median (IQR) 31 (26-40) 39 (29-50) <0.01* 33 (27-42) 39 (27-53) 0.06 30 (25-39) 36 (29-50) <0.01* 
     <25    82 (84.5)   15 (15.5)  
 
<0.01* 
   93 (96.9)    3 (3.1)  
 
0.03* 
   91 (93.8)  6 (6.2)  
 
<0.01* 
     25-44 342 (81.8)   76 (18.2)   428 (97.5) 11 (2.5) 378 (90.4) 40 (9.6) 
     45-64   65 (60.8)   42 (39.2)   101 (91.8)   9 (8.1)    77 (72.0)        30 (28.0) 
     ≥65        21 (77.8)     6 (22.2)    26 (92.9)   2 (7.1)    21 (77.8)      6 (22.2) 
     Missing         4          2             5                 0           5           1 
Sex 
     Male 263 (74.7)   89 (82.8) 0.01* 358 (96.0) 15 (4.0) 0.48 298 (84.7)  54 (5.3) 0.02* 
     Female 245 (25.3)    51 (17.2) 289 (97.0)   9 (3.0) 268 (90.5)        28 (9.5) 
     Missing          6          1               6                 1          6          1 
Country of origin# 
    Butan 114 (76.0)     36 (24.0) 0.57 
 
 
125 (83.3)     25 (16.7) 0.55 
 
 
152 (96.8)  5 (3.2) 0.34 
 
 
    Burma 157 (77.0)         47 (23.0) 179 (87.8)                25 (12.2) 207 (98.1) 4 (1.9) 
    Iraq  65 (83.3)    13 (16.7)  69 (88.5)     9 (14.5)  77 (93.9)  5 (6.1) 
    Somalia         50 (75.8)    16 (24.2)   58 (87.9)     8 (12.1)  63 (94.0)  4 (6.0) 
    Other       126 (81.3)         29 (18.8)        139 (89.7)                16 (10.3)      153 (95.6)          7 (4.4) 
    Missing            2           0              0                  2           0          1  
TB incidence of country of origin# 
     <100 153 (78.9) 41 (21.1) 0.98 191 (95.0)  10 (5.0) 0.60 170 (87.6)  24 (12.4) 0.80 
    100-299 157 (78.9) 42 (21.1)  200 (96.6)                  7 (3.4)  170 (85.4)  29 (14.6)  
    ≥300 171 (77.7) 49 (22.3)   223 (97.4)     6 (2.6)  195 (88.6)   25 (11.4)  
    Unknown        31 (77.5)         9 (22.5)     38 (95.0)      2 (5.0)    35 (87.5)     5 (12.5)  
    Missing          2         0                 1                 0           2          0  
Current smoker 
    No 392 (79.0) 104 (30.0)  
0.41 
497 (97.1)   10 (2.9)  
0.04* 
   436 (87.9) 60 (2.1)  
0.33     Yes 110 (75.9)   35 (24.1) 145 (93.6)   15 (6.4)       123 (84.8)  22 (5.2) 
     Missing        12          2         11                0         13         1 
Alcohol abuse 
     No 397 (79.9) 100 (20.1)  
0.04* 
493 (96.3) 19 (3.7)  
0.82 
442 (88.9)   55 (11.1)  
<0.01*      Yes   98 (71.5)   39 (28.5)  140 (95.9)    6 (4.1)      110 (80.3)   27 (19.7) 
     Missing        19          2          20                0        20          1 
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Clinical information 
 
Blood pressure, mmHg 
    Normal   (<120/80) 280 (82.4) 60 (17.6)  
 
0.05* 
345 (100.0)  0 (0.0)  
 
<0.01* 
312 (91.8)    28 (8.2)  
 
<0.01* 
    Pre-HTN (120-139/80-89) 161 (74.9)  54 (25.1) 229 (100.0)                0 (0.0) 181 (84.2)      34 (15.8) 
    Stage 1-HTN (140-159/90-99)    61 (74.4)  21 (25.6)   68 (78.2) 19 (21.8)   66 (80.5)      16 (19.5) 
    Stage 2-HTN (>160/100)    10 (62.5)     6 (37.5)   11 (64.7)   6 (35.3)   11 (68.8)        5 (31.2) 
     Missing            2          0            2                0           2            0 
BMI, kg/m2 
     Median (IQR) 23.4 
(20.6-26.7) 
25.7 
(22.6-28.4) 
<0.01* 23.9 
(21.0-27.1) 
27.7 
(24.2-30.7) 
<0.01* 22.9 
(20.3-26.3) 
25.7 
(22.9-28.2) 
<0.01* 
     <18.5   39 (88.6)    5 (11.4)  
<0.01* 
    44 (100.0)           0 (0.0)  
0.09 
  42 (95.4)        2 (4.6)  
<0.01*      18.5-24.9 281 (82.9)  58 (17.1)    336 (97.4)           9 (2.6) 309 (91.2)      30 (8.8) 
     25-29.9 137 (73.7)   49 (26.3)    191 (95.5)           9 (4.5)  153 (82.3) 33 (17.7) 
     ≥30   50 (65.0)   27 (35.0)      76 (92.7)           6 (7.3)    61 (79.2)  16 (20.8) 
     Missing           7          2               6           1            7         2  
DM status 
     No DM 311 (82.5)  66 (17.5)  
<0.01* 
388 (99.2) 3 (0.8)  
<0.01* 
345 (91.5)       32 (8.5)  
<0.01*      Pre-DM 169 (76.1)   53 (23.9) 218 (94.0) 14 (6.0) 188 (84.7)  34 (15.3) 
     DM   29 (58.0)   21 (42.0)   45 (84.9)    8 (15.1)   33 (66.0)  17 (34.0) 
     Missing          5          0             2                0           6         0 
Hemoglobin, g/dl 
     Median (IQR) 14.3 
(13.0-15.5) 
14.9 
(13.6-15.9) 
<0.01* 14.5 
(13.1-15.6) 
15.1 
(14.0-16.1) 
0.09 13.9 
(12.8-15.3) 
15.1 
(13.9-16.0) 
<0.01* 
White blood cell, x109/l 
     Median (IQR) 7.1 (5.7-8.3) 7.1 (6.0-8.4) 0.38 7.1 (5.9-8.4) 7.8 (7.0-8.9) 0.10 6.8 (5.6-7.9) 7.5 (6.4-8.8) <0.01* 
Random glucose, mg/dl 
     Median (IQR) 91 (85-99) 94 (86-105) 0.01* 92 (86-100) 109 (94-138) <0.01* 90 (85-97) 95 (88-106) <0.01* 
Creatinine, mg/dl 
     Median (IQR) 0.8 
(0.6-0.9) 
0.8 
(0.7-1.0) 
<0.01* 0.8 
(0.6-0.9) 
0.9 
(0.8-1.0) 
<0.01* 0.74 
(0.60-0.87) 
0.86  
(0.72-0.96) 
<0.01* 
Glycated hemoglobin, % 
     Median (IQR) 5.5 (5.3-5.8) 5.7 (5.4-6.0) <0.01* 5.6 (5.4-5.8) 5.9 (5.8-6.5) <0.01* 5.5 (5.3-5.7) 5.7 (5.4-6.0) <0.01* 
Vitamin D, ng/ml 
     Median (IQR) 20 (15-27) 23 (16-29) 0.04* 21 (15-27) 20 (15-30) 0.90 20 (15-26) 22 (16-28) 0.01* 
     <20 231 (83.1) 47 (16.9)  274 (95.8) 12 (4.2)  248 (89.2) 30 (10.8)  
     20-30      196 (76.9)                  59 (23.1) 0.01* 262 (98.1)   5 (1.9) 0.06 223 (87.5) 32 (12.6)  
     >30        82 (70.1)       35 (29.9)           112 (93.3)   8 (6.7)    96 (82.1) 21 (17.9)  
     Missing          5         0               5                 0            5         0  
HIV status 
     Negative 503 (78.4) 139 (21.6)  
0.90 
640 (96.2) 25 (3.8)  
0.53 
560 (87.2) 82 (12.8)  
0.79      Positive     8 (80.0)      2 (20.0)     10 (100.0)  0 (0.0)     9 (90.0)   1 (10.0) 
     Missing 
 
 
          3           0            3                0          3         0 
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Syphilis, rapid plasma 41eagan test 
     Negative 502 (78.3) 139 (21.7)  
0.58 
639 (96.2) 25 (3.8)  
0.33 
559 (87.2) 82 (12.8)  
0.58      Positive     11 (84.6)      2 (15.4)   13 (100.0)                 0 (0.0)   12 (92.3) 1 (7.7) 
     Missing            1           0           1                 0           1         0 
Hepatitis B, HbsAg 
     Negative 501 (78.7) 136 (21.3)  
0.34 
634 (96.2)   25 (3.8)  
0.41 
554 (87.0) 83 (13.0)  
0.01*      Positive   11 (68.8)     5 (31.2)     17 (100.0)    0 (0.0)     16 (100.0)         0 (0.0) 
     Missing          2          0               2              0           2         0 
Hepatitis B, HbsAb 
     Negative 218 (82.0)    48 (18.0)  
0.07 
270 (97.1)   8 (2.9)  
0.34 
241 (90.6) 25 (9.4)  
0.04*      Positive 295 (76.0)    93 (24.0) 381 (95.7) 17 (4.3) 330 (85.1)    58 (14.9) 
     Missing          1          0               2            0           1          0 
Hepatitis C, antibody 
    Negative 366 (80.6) 88 (19.4)  
0.04* 
456 (97.2) 13 (2.8)  
0.06 
398 (87.7) 56 (12.3)  
0.68     Positive 147 (73.5)  53 (26.5) 196 (94.2)  92 (5.8) 173 (86.5) 27 (13.5) 
    Missing           1                1              0           1  
LTBI  
    QFT Negative 359 (80.0) 90 (20.0) 0.17 446 (96.3) 17 (3.7) 0.98 396 (88.2)  53 (11.8) 0.13 
    QFT Positive 155 (75.0)  51 (25.0) 207 (96.3)   8 (3.7) 176 (85.4)  30 (14.6) 
 
+- LDL-C defined as normal (<130 mg/dl) and elevated (≥130 mg/dl). 
++- Metabolic syndrome defined as Stage 1 (140-159/90-99 mmHg) or Stage 2 Hypertension (>160/100 mmHg) AND elevated TGL (≥150 mg/dl) AND low HDL-C (<40 mg/dl in 
male, <50 mg/dl in female) AND Glycated hemoglobin (≥5.6%). 
+++- Combined dyslipidemia defined as elevated LDL-C (≥130 mg/dl) AND elevated TGL (≥150 mg/dl). 
*-Statistically significant, Chi-square (categorical) or Wilcoxon test (medians), two-sided p-value <0.05 
#- Incidence of active TB case per 100 000 population, WHO Global Tuberculosis Report 2014 
LDL-C=Low density lipoprotein, IQR=Interquartile range, TB=Tuberculosis, HTN=Hypertension, BMI= Body mass index, DM=Diabetes Mellitus, HIV=Human immunodeficiency 
virus, HBsAg= Hepatitis B surface antigen, HBsAb= Hepatitis surface antibody, LTBI= Latent TB Infection, QFT= QuantiFERON®-TB Gold in-Tube test, HDL-C= High density 
lipoprotein, TGL=Triglycerides, WHO-World Health Organization. 
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Supplemental Table 2. Binary association between LTBI and LDL-C, Metabolic Syndrome and 
Combined dyslipidemia  
 Crude OR (95% CI) Adjusted OR (95%)* 
Odds of LDL-C as ≥130 mg/dl (n=655)   
     LTBI negative Ref Ref 
     LTBI positive 1.31 (0.89-1.94) 1.22 (0.82-1.83) 
Odds of metabolic syndrome (n=678)  
     LTBI negative Ref Ref 
     LTBI positive 1.01 (0.43-2.39) 0.92 (0.38-2.23) 
Odds of combined dyslipdemia (n=655)  
 
     LTBI negative Ref Ref 
     LTBI positive 1.27 (0.79-2.06) 1.14 (0.69-1.88) 
 
*-Adjusted for age group, gender, body mass index, and diabetes mellitus 
+- LDL -Cdefined as normal (<130 mg/dl) and elevated (≥130 mg/dl). 
++- Metabolic syndrome defined as Stage 1 (140-159/90-99 mmHg) or Stage 2 Hypertension ((>160/100 mmHg) 
AND elevated TGL (≥150 mg/dl) AND low HDL-C (<40 mg/dl in male, <50 mg/dl in female) AND Glycated 
hemoglobin (≥5.6%). 
+++- Combined dyslipidemia defined as elevated LDL-C (≥130 mg/dl) AND elevated TGL (≥150 mg/dl). 
-Missing values of covariates were coded as level of covariates 
LTBI= Latent TB Infection, LDL-C = density lipoprotein, OR=Odds ratio, CI=Confidence interval. 
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Supplemental Table 3. Latent TB infection and interaction between age group and body 
mass index with dyslipidemia 
 
Age group Lipid level Prevalence LTBI OR (95%CI) 
     
 <25 years old 
Elevated total cholesterol (≥200 mg/dl) 31.3% 1.71 (0.52-5.60) 
Normal total cholesterol (<200 mg/dl 21.0%  
     
 25-44 years old 
Elevated total cholesterol (≥200 mg/dl) 33.6% 1.23 (0.79-1.93) 
Normal total cholesterol (<200 mg/dl 29.1%  
   
   45-64 years old 
Elevated total cholesterol (≥200 mg/dl) 42.9% 1.12 (0.53-2.40) 
Normal total cholesterol (<200 mg/dl 40.0%  
    
  ≥65 years old 
Elevated total cholesterol (≥200 mg/dl) 43.8% 0.92 (0.20-4.18) 
Normal total cholesterol (<200 mg/dl 41.7%  
    
  <25 years old 
Lower HDL-C* 20.0% 1.30 (0.49-3.48) 
Normal HDL-C** 24.6%  
     
 25-44 years old 
Lower HDL-C* 28.0% 1.22 (0.81-1.84) 
Normal HDL-C** 32.1%  
     
 45-64 years old 
Lower HDL-C* 41.8% 0.97 (0.46-2.06) 
Normal HDL-C** 41.1%  
     
 ≥65 years old 
Lower HDL-C* 23.1% 5.0 (0.96-26.12) 
Normal HDL-C** 60.0%  
      
<25 years old 
Elevated triglycerides (≥150 mg/dl) 17.4% 0.66 (0.20-2.18) 
Normal triglycerides (<150 mg/dl) 24.3%  
     
 25-44 years old 
Elevated triglycerides (≥150 mg/dl) 30.9% 1.05 (0.69-1.59) 
Normal triglycerides (<150 mg/dl) 29.9%  
      
45-64 years old 
Elevated triglycerides (≥150 mg/dl) 47.8% 2.05 (0.91-4.58) 
Normal triglycerides (<150 mg/dl) 31.0%  
      
≥65 years old 
Elevated triglycerides (≥150 mg/dl) 46.7% 1.40 (0.31-6.33) 
Normal triglycerides (<150 mg/dl) 38.5%  
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BMI Lipid level Prevalence 
LTBI 
OR (95%CI) 
 
<18.5 kg/m2 
Elevated total cholesterol (≥200 mg/dl) 22.2% 0.48 (0.90-2.69) 
Normal total cholesterol (<200 mg/dl 37.1%  
 
18.5-24.9 kg/m2 
Elevated total cholesterol (≥200 mg/dl) 26.7% 1.88 (1.13-3.14) 
Normal total cholesterol (<200 mg/dl 40.7%  
 
25-29.9 kg/m2 
Elevated total cholesterol (≥200 mg/dl) 41.3% 1.31 (0.73-2.36) 
Normal total cholesterol (<200 mg/dl 34.9%  
 
≥30 kg/m2 
Elevated total cholesterol (≥200 mg/dl) 23.9% 1.06 (0.39-2.92) 
Normal total cholesterol (<200 mg/dl) 25.0%  
 
<18.5 kg/m2 
Lower HDL-C* 35.7% 0.90 (0.24-3.41) 
Normal HDL-C** 33.3%  
 
18.5-24.9 kg/m2 
Lower HDL-C* 27.1% 1.27 (0.79-2.05) 
Normal HDL-C** 32.1%  
 
25-29.9 kg/m2 
Lower HDL-C* 33.3% 1.41 (0.80-2.51) 
Normal HDL-C** 41.4%  
 
≥30 kg/m2 
Lower HDL-C* 24.5% 0.99 (0.35-2.76) 
Normal HDL-C** 24.2%  
 
<18.5 kg/m2 
Elevated triglycerides (≥150 mg/dl) 16.7% 0.34 (0.34-3.24) 
Normal triglycerides (<150 mg/dl) 36.8%  
 
18.5-24.9 kg/m2 
Elevated triglycerides (≥150 mg/dl) 37.3% 1.65 (1.03-2.65) 
Normal triglycerides (<150 mg/dl) 26.5%  
 
25-29.9 kg/m2 
Elevated triglycerides (≥150 mg/dl) 39.1% 1.17 (0.66-2.07) 
Normal triglycerides (<150 mg/dl) 35.4%  
 
≥30 kg/m2 
Elevated triglycerides (≥150 mg/dl) 25.0% 1.07 (0.39-3.00) 
Normal triglycerides (<150 mg/dl) 23.4%  
*Lower HDL-C (<40 mg/dl in male, <50 mg/dl in female)  
**Normal HDL-C (≥40 mg/dl in male, ≥50 mg/dl in female) 
 
 
 
 
 
 
 
 
 
 
 
 45 
 
Supplemental Table 4. Latent TB infection and interaction between diabetes and vitamin D 
with dyslipidemia 
 
 Lipid level Prevalence LTBI OR (95%CI) 
DM-yes Elevated total cholesterol (≥200 mg/dl) 46.7% 1.36 (0.45-4.10) 
Normal total cholesterol (<200 mg/dl) 39.1% 
DM-no Elevated total cholesterol (≥200 mg/dl) 31.1% 1.41 (0.85-2.32) 
Normal total cholesterol (<200 mg/dl) 24.2% 
Vitamin D-low Elevated total cholesterol (≥200 mg/dl) 32.9% 1.32 (0.75-2.32) 
Normal total cholesterol (<200 mg/dl) 27.1% 
Vitamin D-normal Elevated total cholesterol (≥200 mg/dl) 39.1% 1.39 (0.90-2.15) 
Normal total cholesterol (<200 mg/dl) 31.6% 
DM-yes Lower HDL-C* 50.0% 0.53 (0.17-1.63) 
Normal HDL-C** 34.8% 
DM-no Lower HDL-C* 20.5% 1.6 (0.99-2.60) 
Normal HDL-C** 29.3% 
Vitamin D-low Lower HDL-C* 26.2% 1.26 (0.75-2.09) 
Normal HDL-C** 30.9% 
Vitamin D-normal Lower HDL-C* 32.1% 1.39 (0.90-2.15) 
Normal HDL-C** 35.7% 
DM-yes Elevated triglycerides (≥150 mg/dl) 48.6% 1.89 (0.58-6.17) 
Normal triglycerides (<150 mg/dl) 33.3% 
DM-no Elevated triglycerides (≥150 mg/dl) 28.7% 1.23 (0.77-1.98) 
Normal triglycerides (<150 mg/dl) 24.6% 
Vitamin D-low Elevated triglycerides (≥150 mg/dl) 33.6% 1.46 (0.87-2.46) 
Normal triglycerides (<150 mg/dl) 25.8% 
Vitamin D-normal Elevated triglycerides (≥150 mg/dl) 35.3% 1.09 (0.71-1.66) 
Normal triglycerides (<150 mg/dl) 33.3% 
 
*Lower HDL-C (<40 mg/dl in male, <50 mg/dl in female)  
*Normal HDL-C (≥40 mg/dl in male, ≥50 mg/dl in female) 
 
 
